Background/Aims: Phosphatase and tensin homolog (PTEN) is a known tumor suppressor gene that is downregulated in hepatocellular carcinoma (HCC). Here, we investigated the association between single nucleotide polymorphisms (SNPs) of PTEN and HCC development in patients with hepatitis B virus (HBV) infection.
and third most common cause of cancer-related deaths globally. 1 Hepatitis B virus (HBV) infection is one of the most significant causes of HCC, and genetic alterations in HBV virus were reported to be associated with HCC development and characteristics. 2, 3 However, further research on host genetic determinants is warranted for the development of HCC in patients with chronic HBV infection.
Phosphatase and tensin homolog (PTEN ) deleted on chromosome 10 is a well-known tumor suppressor in several cancer types. PTEN can dephosphorylate phosphoinositide 3-kinase, which in turn regulates protein kinase B Akt ex-http://www.livercancer.or.kr pression. This regulatory mechanism has downstream effects on transcription, proliferation, cell survival, invasiveness, and angiogenesis. 4 PTEN is also linked with several mechanisms related to the p53 tumor suppressor. Through p53 and other mechanisms, PTEN loss leads to genomic instability. 5 Any decrease in PTEN expression was shown to be correlated with increased tumor grade, advanced disease stage, and poor prognosis. 6 PTEN expression is reduced in nearly half of HCC cases either via mutation or methylation, which may further reduce its expression. 6 At the cellular level, PTEN is a target in the pathogenic pathway of hepatitis C virus core protein and HBV X protein. 7, 8 Single nucleotide polymorphisms (SNPs) are one of the most commonly occurring forms of genetic variations in the human genome. Several SNPs in genes such as p53 and tumor necrosis factor-alpha as well as those related to Wnt/ β-catenin pathway have been associated with the risk of HCC development. [9] [10] [11] However, the effects of PTEN polymorphism on HCC risk in patients with chronic HBV infection have been rarely reported. 12 In the present study, we evaluated the relationship between PTEN polymorphism and HCC risk in two independent chronic HBV infection population. was generated using known λ DNA concentrations.
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Study subjects
Genotyping
The validated SNPs in PTEN were identified using a public SNP database (http://www.ncbi.nlm.nih.gov/projects/SNP/).
For the development population, we chose six SNPs with minor allele frequency ≥5% and r 2 ≥0.8, as per the literature review. Thus, we analyzed the SNPs at six polymorphic sites, namely, positions rs1234221 (A to C substitution), rs1903860
(T to C substitution), rs1234220 (A to G substitution), rs1903858 (A to G substitution), rs2299941 (A to G substitution), and rs17431184 (T to C substitution) ( Table 1 ). Genotyping was performed using GoldenGate genotyping assay kit according to standard protocols (Illumina Inc., San Diego, CA, USA) as previously described. 15 Signal intensities were extracted and analyzed using BEADSTUDIO software ver.
(Illumina Inc.).
For the validation population, we selected three SNPs (rs1903860, rs1903858, and rs2299941) based on the results from the development population.
Statistical analysis
Statistical analysis was performed using IBM SPSS ver.
22.0 (IBM Corp., Armonk, NY, USA). Maintenance of Hardy-Weinberg equilibrium for each SNP was investigated to determine any deviation in genotype frequency using χ 2 tests.
Genetic models used in association testing were the co-dominant, dominant, and recessive models.
We analyzed the association between genotype and HCC presence using a multiple logistic regression model by controlling for covariates such as age and gender. In this analysis, chronic HBV carriers without HCC were regarded as the control group, while their analysis results were compared with those of HBV-associated patients with HCC. For the validation population, the association between HCC development and genotype was analyzed using multivariate Cox regression analysis.
The presence of a linkage disequilibrium (LD) block of SNPs was confirmed using HAPLOVIEW software (version 4.0; http://www.broad.mit.edu/mpg/haploview). Individual haplotypes were inferred using the EM algorithm with the SAS haplotype procedure. Haplotype analysis was performed using multiple logistic regression. All statistical tests were two-tailed and statistical significance was set at P <0.05. For more precise estimates, statistical computation was used to determine P values of Fisher's exact test with Monte Carlo simulation (number of iteration=100,000). rESuLtS
Patients characteristics
Baseline demographic and clinical parameters of development population were shown as chronic HBV carriers without HCC and patients with HBV-associated HCC (Table 2) .
Patients with HCC were older than chronic HBV carriers without HCC, and men predominated both groups. Clinicopathologic characteristics that estimated the severity of cancer among the enrolled patients with HCC are depicted in Table 2 . Serum levels of alpha-fetoprotein greater than 400 ng/mL were detected in approximately one-third of patients.
In total, 108 patients (44.5%) had HCC larger than 5 cm in diameter, and 77 patients (31.8%) exhibited vascular inva- Baseline characteristics of validation population are shown in Table 3 . About one-third of the validation population was detected positive for hepatitis B e-antigen, and 20% patients had decompensated cirrhosis. In total, 41 patients from the validation population developed HCC during the course of entecavir therapy. The mean HCC size was 2.8±2.4 cm, while the mean number of HCC was 1.3±0.5.
Genotype distribution and haplotype construction
The (Fig. 1A) . For the validation population, four common haplotypes T-A-A, C-G-G,
T-G-A, and G-G-A at rs1903860, rs1903858, and rs2299941
positions were estimated. The values of (D') ranged from 0.986 to 1.000, while those of r 2 ranged from 0.553 to 0.833 (Fig. 1B) .
3. Association between genotype/haplotype frequency and presence of HCC in the development population
The relationship between development of HCC and genotype/haplotype frequencies of the six SNPs in PTEN was investigated among chronic HBV carriers ( 
Association between PTEN genotype/haplotype frequency and development of HCC in the validation population
We evaluated the relationship between PTEN rs1903860, rs1903858, and rs2299941 genotypes/haplotypes and HCC development using the validation population including patients with HBV-related liver cirrhosis. Among 200 patients, 41 (20.5%) developed HCC during the follow-up period (median, 58.8 months; range, 6-100 months). One SNP and Values are presented as number (%) unless otherwise indicated. PTEN, phosphatase and tensin homolog; HCC, hepatocellular carcinoma.
one haplotype were associated with low risk of HCC development (Table 5) . Kaplan-Meier survival estimates revealed the association between patients with PTEN rs2299941 G allele and low risk of HCC development (P =0.069, Fig. 2 polymorphism associated with HCC development in both development and validation groups and was previously assessed in patients with prostate or endometrial cancer by other researchers. However, these studies failed to reveal any association between PTEN polymorphism and cancer. 23, 24 Therefore, the present study is the first report to demonstrate the relationship between PTEN rs2299941 polymorphism and cancer.
Our study has some limitations. We failed to demonstrate the direct function of PTEN rs2299941 SNP in HCC carcinogenesis. In fact, rs2299941 SNP is located within an intron and does not directly alter the protein-coding sequence of PTEN. However, the majority of reports on disease-associated mutations describing the variants that directly alter the protein-coding sequence of a gene failed to consider other mechanisms involved in gene function alterations. In cases where mutations are not found, polymorphism that resides outside of the coding region may be often overlooked. Such mechanisms include alteration in gene regulation via disruption of trans -acting factor(s) and cis-acting sequence-element interactions and may result in a pathologic state. A previous study with haplotype-based approaches reported a significant association between PTEN SNPs, including rs2299941, and Cowden and Bannayan-Riley-Ruvalcaba syndromes. 25 Here, we validated the predictive ability of PTEN SNPs in a population of HBV-related liver cirrhosis. The majority of previous studies on disease-associated mutations are based on case-control study design. The present study initially evaluated six candidate PTEN SNPs in a case-control study design and then validated three PTEN SNPs in a retrospective cohort population. This is an important feature of the current study as compared to previous studies on gene polymorphism and cancer. 
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